NCT04230239 - Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 26, 2019

Primary Completion Date

April 30, 2021

Study Completion Date

August 11, 2021

Conditions

Newly Diagnosed Secondary or High Risk AML

Interventions

DRUG

CPX-351

"CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine"

Trial Locations (12)

Unknown

Institut Català D'Oncologia-Hospital Germans Trias I Pujol, Badalona

Institut Català D'Oncologia - Hospital Duran I Reynals, Bellvitge

Hospital San Pedro de Alcántara, Cáceres

Hospital Universitario Reina Sofía, Córdoba

Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas

Hospital Universitario Lucus Augusti, Lugo

Hospital Ramón Y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Central de Asturias, Oviedo

Hospital General Del H.U. Virgen Del Rocío, Seville

Hospital Clínico Universitario de Valencia, Valencia

Hospital Universitario Y Politécnico La Fe, Valencia

All Listed Sponsors

lead

PETHEMA Foundation

OTHER